Dr. Kamat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2001 - 2003
West Virginia UniversityChief Residency, Urology, 2000 - 2001- West Virginia UniversityResidency, Urology, 1997 - 2000
- West Virginia UniversityResidency, Surgery, 1995 - 1997
Seth G.S. Medical CollegeClass of 1994
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2002 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025- American Board of Urology Urology
- Join now to see all
Awards, Honors, & Recognition
- Compassionate Doctor Award
- Top Doctors in America
- Who's Who in Medicine
- Join now to see all
Clinical Trials
- Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium Start of enrollment: 2003 Dec 01
- Markers of Response to Intravesical Bladder Cancer Therapy Start of enrollment: 2005 Jun 01
Publications & Presentations
PubMed
- 1 citationsLong-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Drupad Annapureddy, Jeffrey Howard
BJU International. 2025-02-01 - 1 citationsPredicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: D...Yair Lotan, Viswesh Krishna, Waleed M Abuzeid, Bryn Launer, Sam S Chang
The Journal of Urology. 2025-02-01 - Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.Siamak Daneshmand, Ashish M Kamat, Neal D Shore, Joshua J Meeks, Matthew D Galsky
Urologic Oncology. 2025-01-15
Journal Articles
- Seminars Article New Horizons in Bladder Cancer ResearchStephen B Williams, Ashish M Kamat, ScienceDirect
- Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer—ReplyAshish M Kamat, Stephen B Williams, JAMA
- Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018Ashish M Kamat, Yair Lotan, European Urology
- Join now to see all
Authored Content
- Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018September 2018
- Recommendations for Follow-up of Muscle-Invasive Bladder Cancer Patients: A Consensus by the International Bladder Cancer NetworkFebruary 2018
- Contribution of Bladder Cancer Pathology Assessment in Planning Clinical TrialsFebruary 2018
Press Mentions
Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve SurvivalNovember 6th, 2024- Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastMay 17th, 2024
- Clinical Trials for Bladder CancerSeptember 3rd, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
